A Phase 4 interventional study of Vonoprazan and Lansoprazole in Erosive Esophagitis, sponsored by Takeda. Completed at 36 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-12-13.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing vonoprazan in Esophagitis — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Esophagitis.
Among the 10 studies testing vonoprazan in Esophagitis, this one is the 8th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 4, and was the 7th registered.
123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.
Browse Esophagitis studies →1 of the 10 studies testing vonoprazan in Esophagitis is open now, in 1 country. Recruiting first, the newest first:
Indonesia University · Sites in Indonesia
Ages 18+
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2016.
This study's enrollment of 208 is above the median of 96 across 99 interventional studies indexed under Esophagitis.
Median enrollment 357 across the 10 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
11 studies in Esophagitis by Takeda: none open now, none under way, none of them phase 3. Of 11 finished, 4 (36%) have results posted.
Among the 11 studies in Esophagitis by Takeda, this one is the 7th largest by enrollment, is one of 2 that started in 2016, is the only one in phase 4, and was the 10th registered.
Takeda’s Esophagitis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing vonoprazan in Esophagitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 11 in Esophagitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is exploratorily evaluate the effect on gastric mucosal tissue and the safety of long-term administration (260 weeks: 5 years) of vonoprazan 10 mg or 20 mg in patients receiving maintenance treatment after healed erosive esophagitis (EE), and the curative effect of vonoprazan 20 mg versus lansoprazole in patients with EE.
This is a multicenter, open-label, randomized, parallel-group study to exploratorily evaluate the effect on gastric mucosal tissue and the safety of long-term administration of vonoprazan in maintenance treatment after healed EE, and the curative effect of vonoprazan versus lansoprazole in participants with EE.
Participants endoscopically diagnosed with EE of Los Angeles (LA) Classification Grades A to D at the start of treatment (Week 0 of the healing phase) will be randomly assigned to receive either vonoprazan 20 mg or lansoprazole 30 mg to be taken once daily for up to 8 weeks. Subjects with healed EE as confirmed endoscopically at Week 4 or 8 in the healing phase will enter the maintenance phase.
In the maintenance phase, the vonoprazan group and the lansoprazole group will be administered a starting dose of 10 mg and 15 mg, respectively, once daily up to 260 weeks.
If the principal investigator or investigator judged the effect of vonoprazan 10 mg or lansoprazole 15 mg to be insufficient as the maintenance treatment of EE, vonoprazan and lansoprazole may be increased to 20 mg and 30 mg, respectively.
The research period will consist of two subperiods: healing phase in which participants with EE will receive treatment (for 4 or 8 weeks) and maintenance phase in which participants will receive maintenance treatment (for 260 weeks), and thus, a total of up to 268 weeks. The number of visits will be a maximum of 18 visits. Planned number of research subjects, as the number of research subjects for entry to the maintenance phase, will be 130 participants in the vonoprazan group and 65 participants in the lansoprazole group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healing Phase:
Therapeutic category: Ambulatory
Maintenance Phase:
Participants who have endoscopically confirmed EE healing* (mucous membrane disorder is not observed) at completion of the healing phase (Week 4 or 8 of the healing phase)
* Participants who are classified as grade 0 according to severity classification of EE (See Table 9.b)
Exclusion Criteria:
Healing Phase:
Participants who have been determined to be inappropriate as subjects in the study by the principal investigator or investigator
Maintenance Phase:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vonoprazan 20 mg administered orally once daily in the healing phase + vonoprazan 10 mg (as the initial dose and adjusted to vonoprazan 10 mg or 20 mg) administered orally once daily in the maintenance phase
Drug: Vonoprazan
Lansoprazole 30 mg administered orally once daily in the healing phase + lansoprazole 15 mg (as the initial dose and adjusted to lansoprazole 15 mg or 30 mg) administered orally once daily in the maintenance phase
Drug: Lansoprazole
Vonoprazan fumarate 10 mg or 20 mg capsules
Lansoprazole 15 mg or 30 mg capsules
Number of Participants With Malignant Alteration of Epithelial Cells
Numbers of participants with malignant alteration of epithelial cells for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.
Time frame: Time Frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Parietal Cell Protrusion/Hyperplasia
Numbers of participants with parietal cell protrusion/hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Foveolar Hyperplasia
Numbers of participants with foveolar hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Enterochromaffin-like-cell Hyperplasia
Numbers of participants with enterochromaffin-like-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With G-cell Hyperplasia
Numbers of participants with G-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Percentage of Participants With Recurrence of Erosive Esophagitis (EE)
Erosive esophagitis recurrence is defined as endoscopically confirmed to have erosive esophagitis (LA classification grades O and A to D) during the Maintenance Phase. The LA classification graded as follows- Grade O: normal mucosa; Grade A: nonconfluent mucosal breaks \<5 mm in length; Grade B: nonconfluent mucosal breaks ≥ 5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Percentage of Participants Who Healed EE at the End of Healing Phase
Percentage of participants who healed EE at the end of healing phase was reported.
Time frame: Up to Week 8
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) in Maintenance Phase
Number of participants reporting one or more TEAEs in Maintenance Phase was reported. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: 260 weeks (Baseline, up to the end of Maintenance Phase)
Number of Participants With Fundic Gland Polyp
Numbers of participants with fundic gland polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Hyperplastic Polyp
Numbers of participants with hyperplastic polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Cobblestone Mucosa
Numbers of participants with cobblestone mucosa for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Multiple White and Flat Elevated Lesions
Numbers of participants with multiple white and flat elevated lesions for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Black Spots
Numbers of participants with black spots for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Middle Gastric Body
Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Antrum
Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Neutrophilic Infiltration in Greater Curvature of Middle Gastric Body
Numbers of participants with neutrophilic infiltration in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Neutrophilic Infiltration in Greater Curvature of Antrum
Numbers of participants with neutrophilic infiltration in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Atrophy in Greater Curvature of Middle Gastric Body
Numbers of participants with atrophy in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Atrophy in Greater Curvature of Antrum
Numbers of participants with atrophy in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Intestinal Metaplasia in Greater Curvature of Middle Gastric Body
Numbers of participants with intestinal metaplasia in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Intestinal Metaplasia in Greater Curvature of Antrum
Numbers of participants with intestinal metaplasia in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Presence of H.Pylori in Greater Curvature of Middle Gastric Body
Numbers of participants with presence of H.pylori in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Presence of H.Pylori in Greater Curvature of Antrum
Numbers of participants with presence of H.pylori in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Number of Participants With Gastric Polyp
Numbers of participants with gastric polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported. The number analyzed is the number of participants with data available for analysis.
Time frame: Up to Week 268 (Week 260 in Maintenance Phase)
Participants took part in the survey at 36 investigative sites in Japan, from 20 March 2016 to 5 March 2022.
| Milestone | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Started | 139 | 69 |
| Completed | 137 | 68 |
| Not completed | 2 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Milestone | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Started | 137 | 68 |
| Completed | 105 | 53 |
| Not completed | 32 | 15 |
| Withdrew: Adverse event | 12 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 15 | 8 |
| Withdrew: Other | 5 | 4 |
Numbers of participants with malignant alteration of epithelial cells for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Malignant Alteration of Epithelial Cells | 0 | 0 |
Numbers of participants with parietal cell protrusion/hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Parietal Cell Protrusion/Hyperplasia | 99 | 45 |
Numbers of participants with foveolar hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Foveolar Hyperplasia | 15 | 1 |
Numbers of participants with enterochromaffin-like-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Enterochromaffin-like-cell Hyperplasia | 5 | 4 |
Numbers of participants with G-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With G-cell Hyperplasia | 87 | 40 |
Erosive esophagitis recurrence is defined as endoscopically confirmed to have erosive esophagitis (LA classification grades O and A to D) during the Maintenance Phase. The LA classification graded as follows- Grade O: normal mucosa; Grade A: nonconfluent mucosal breaks \<5 mm in length; Grade B: nonconfluent mucosal breaks ≥ 5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.
| Percentage of participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Percentage of Participants With Recurrence of Erosive Esophagitis (EE) | 3.8 (1.1 to 9.6) | 11.3 (4.3 to 23.0) |
Percentage of participants who healed EE at the end of healing phase was reported.
| Percentage of participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Percentage of Participants Who Healed EE at the End of Healing Phase | 1.4 (0.2 to 5.1) | 0.0 (0.0 to 5.2) |
Number of participants reporting one or more TEAEs in Maintenance Phase was reported. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) in Maintenance Phase | 126 | 64 |
Numbers of participants with fundic gland polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Fundic Gland Polyp | 75 | 45 |
Numbers of participants with hyperplastic polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Hyperplastic Polyp | 24 | 6 |
Numbers of participants with cobblestone mucosa for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Cobblestone Mucosa | 23 | 8 |
Numbers of participants with multiple white and flat elevated lesions for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Multiple White and Flat Elevated Lesions | 8 | 9 |
Numbers of participants with black spots for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Black Spots | 8 | 7 |
Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Middle Gastric Body | 15 | 9 |
Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Antrum | 11 | 9 |
Numbers of participants with neutrophilic infiltration in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Neutrophilic Infiltration in Greater Curvature of Middle Gastric Body | 1 | 0 |
Numbers of participants with neutrophilic infiltration in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Neutrophilic Infiltration in Greater Curvature of Antrum | 0 | 0 |
Numbers of participants with atrophy in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Atrophy in Greater Curvature of Middle Gastric Body | 0 | 0 |
Numbers of participants with atrophy in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Atrophy in Greater Curvature of Antrum | 7 | 7 |
Numbers of participants with intestinal metaplasia in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Intestinal Metaplasia in Greater Curvature of Middle Gastric Body | 0 | 0 |
Numbers of participants with intestinal metaplasia in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Intestinal Metaplasia in Greater Curvature of Antrum | 6 | 6 |
Numbers of participants with presence of H.pylori in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Presence of H.Pylori in Greater Curvature of Middle Gastric Body | 0 | 0 |
Numbers of participants with presence of H.pylori in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Presence of H.Pylori in Greater Curvature of Antrum | 0 | 0 |
Numbers of participants with gastric polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported. The number analyzed is the number of participants with data available for analysis.
| Participants | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Number of Participants With Gastric Polyp | 82 | 46 |
Collected over Up to Week 268 (Week 260 in Maintenance Phase). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vonoprazan Group | 0/139 (0%) | 50/139 (36%) | 128/139 (92.1%) |
| Lansoprazole Group | 1/69 (1.4%) | 27/69 (39.1%) | 65/69 (94.2%) |
| Event | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| CataractEye disorders | 3/139 | 6/69 |
| Large intestine polypGastrointestinal disorders | 5/139 | 4/69 |
| Inguinal herniaGastrointestinal disorders | 2/139 | 2/69 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/139 | 2/69 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/139 | 2/69 |
| Thrombotic cerebral infarctionNervous system disorders | 0/139 | 2/69 |
| Diverticulum intestinal haemorrhagicGastrointestinal disorders | 3/139 | 0/69 |
| Carpal tunnel syndromeNervous system disorders | 3/139 | 1/69 |
| Acute myocardial infarctionCardiac disorders | 1/139 | 1/69 |
| Angina unstableCardiac disorders | 0/139 | 1/69 |
| Event | Vonoprazan Group | Lansoprazole Group |
|---|---|---|
| Gastric polypsGastrointestinal disorders | 62/139 | 31/69 |
| NasopharyngitisInfections and infestations | 49/139 | 29/69 |
| Gastric mucosal lesionGastrointestinal disorders | 30/139 | 17/69 |
| EczemaSkin and subcutaneous tissue disorders | 10/139 | 10/69 |
| Gastritis erosiveGastrointestinal disorders | 12/139 | 9/69 |
| HypertensionVascular disorders | 15/139 | 6/69 |
| BronchitisInfections and infestations | 13/139 | 7/69 |
| DiarrhoeaGastrointestinal disorders | 13/139 | 6/69 |
| InfluenzaInfections and infestations | 13/139 | 1/69 |
| Back painMusculoskeletal and connective tissue disorders | 13/139 | 3/69 |
Randomized Set: All participants who were enrolled in Healing Phase and who received at least one dose of any therapy during the study.
| Age, Continuous(years) | Vonoprazan Group | Lansoprazole Group | Total |
|---|---|---|---|
| Mean | 60.5 ± 11.90 | 61.8 ± 12.13 | 60.9 ± 11.97 |
| Sex: Female, Male(Participants) | Vonoprazan Group | Lansoprazole Group | Total |
|---|---|---|---|
| Female | 41 | 27 | 68 |
| Male | 98 | 42 | 140 |
| Race and Ethnicity Not Collected(Participants) | Vonoprazan Group | Lansoprazole Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Vonoprazan Group | Lansoprazole Group | Total |
|---|---|---|---|
| Japan | 139 | 69 | 208 |
| Height(Centimeters (cm)) | Vonoprazan Group | Lansoprazole Group | Total |
|---|---|---|---|
| Mean | 164.4 ± 8.96 | 162.7 ± 10.12 | 163.8 ± 9.37 |
| Weight(Kilograms (kg)) | Vonoprazan Group | Lansoprazole Group | Total |
|---|---|---|---|
| Mean | 68.55 ± 13.011 | 65.98 ± 11.520 | 67.70 ± 12.566 |
| BMI (Body Mass Index)(Kilogram (kg)/meter (m)^2) | Vonoprazan Group | Lansoprazole Group | Total |
|---|---|---|---|
| Mean | 25.25 ± 3.737 | 24.85 ± 3.280 | 25.12 ± 3.589 |
| Smoking History(Participants) | Vonoprazan Group | Lansoprazole Group | Total |
|---|---|---|---|
| Never Smoked | 52 | 31 | 83 |
| Current Smoker | 25 | 9 | 34 |
| Ex-Smoker | 62 | 29 | 91 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2016 to primary completion in Mar 2022, 71 months.
Results were first posted in Dec 2023, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan